New combo therapy aims to fight bladder cancer without surgery
NCT ID NCT04106115
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether combining the immunotherapy drug durvalumab with a cancer vaccine (S-488210/S-488211) can help people with a type of bladder cancer that has not responded to standard treatment. The trial includes adults with high-risk non-muscle invasive bladder cancer who cannot or choose not to have their bladder removed. Participants receive the drug intravenously and the vaccine as injections under the skin, and researchers monitor for side effects and how long the cancer stays away.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and S-488210/S-488211 vaccine
What this could lead to
If successful, this combination could offer a new treatment option for people with high-risk bladder cancer who have not responded to standard therapy, potentially avoiding the need for bladder removal.
What could go wrong
This is an early-phase trial with a small number of participants, so the results may not apply to everyone. The combination may cause side effects, and it is not yet known if it will be more effective than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University NHS FT
RECRUITINGCambridge, United Kingdom
Contact
-
Guy's and St Thomas' NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact
-
Royal Free London NHS FT
RECRUITINGLondon, United Kingdom
Contact
-
The Christie NHS Foundation Trust
RECRUITINGManchester, United Kingdom
Contact
-
The Royal Marsden NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact
-
University College London Hospital NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact
-
University Hospital Southampton NHS Foundation Trust
RECRUITINGSouthampton, United Kingdom
Contact